|
Mar 3
|
FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults
|
|
Mar 2
|
Phase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food Allergies
|
|
Feb 28
|
CHMP recommends EU approval of Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
|
|
Feb 28
|
Immune-Onc doses first subject in trial of IO-108 for HCC
|
|
Feb 14
|
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
|
|
Feb 12
|
FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
|
|
Feb 12
|
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
|
|
Feb 10
|
Is Roche Holding AG (RHHBY) The Best Annual Dividend Stock To Buy Now?
|
|
Jan 30
|
Roche's 2024 Sales and Earnings Beat, Key Drugs Perform Well
|
|
Jan 30
|
FDA grants 510(k) clearance to Roche’s Tina-quant molarity assay
|
|
Jan 30
|
Roche Expects Sales, Earnings Growth After Better-Than-Expected Results
|
|
Jan 30
|
Roche sees high single-digit core profit growth in 2025
|
|
Jan 30
|
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth
|
|
Jan 29
|
Roche appoints chief digital technology officer
|
|
Jan 29
|
Change to the Roche Enlarged Corporate Executive Committee
|
|
Jan 28
|
Roche reports positive topline outcomes from DMD treatment trial
|
|
Jan 28
|
Genentech’s Itovebi Demonstrated Statistically Significant and Clinically Meaningful Overall Survival Benefit in a Certain Type of HR-Positive Advanced Breast Cancer
|
|
Jan 28
|
Roche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer
|
|
Jan 27
|
Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD)
|
|
Jan 24
|
Stocks to watch this week: ASML, Intel, LVMH, Shell and Glencore
|